RFA-GH-21-006, Establishing the Southeast Asia Serological Surveillance Network (SASSNet) for Emergent, Endemic, and Vaccine-Preventable Infections

项目概要 该项目旨在建立东南亚血清学监测网络 (SASSNet) 以及印度尼西亚和越南的业务。网络将应用优化和 经验证的血清学采样、分析和暴露于新出现和 具有区域重要性的被忽视的热带传染病。项目 利用机器人 ELISA 和 Luminex 多重高通量平台，以便 有效、可持续地监测数十种感染/疫苗接种。抽样策略是 按年龄分层的匿名残留血液样本的实用方法 印度尼西亚 25 家医院和越南 20 家医院组成的网络。该项目加入学术 来自牛津大学印度尼西亚临床研究单位的研究合作伙伴以及 越南与两国卫生部的研究人员合作。第一个 今年的工作重点是 SARS-CoV-2 至 3 年的血清学监测 不同的工作流程：1) 通过 ELISA 建立常规国家血清学监测； 2） 在选定地点进行 SARS-CoV 暴露情况的横断面调查； 3）以下两个 一年内通过 ELISA 进行血清学评估的纵向队列，其中 SARS-CoV-2 qPCR 呈阳性后立即入组 其他在接种 COVID-19 疫苗后立即进行。第一年还将看到优化 对六种不同 SARS-CoV-2 抗原靶点的多重 Luminex 检测进行验证 三种不同的免疫球蛋白（A、M 和 G），以及 Spike S1 和 Spike N 蛋白 MERS-CoV 和四种季节性冠状病毒。相同的多重检测稍后将包括 八种新出现的感染（例如尼帕病毒、寨卡病毒和日本脑炎病毒）被忽视 热带感染（例如登革热、疟疾、丝虫病、麻风病和肠道蠕虫病）， 和疫苗可预防的感染（例如麻疹、白喉和破伤风）。那个多路复用器 血清学检测将构成常规国家血清学监测的基础，并且 该项目旨在在印度尼西亚卫生部的设施内建设这种能力 越南，并在 5 月底将这些设施移交给各自当局 项目寿命年。

Project Summary The project aims to establish the Southeast Asian Serological Surveillance Network (SASSNet) and operations in Indonesia and Viet Nam. The Network will apply optimized and validated serological sampling, analysis, and reporting of exposures to emerging and endemic neglected tropical infectious diseases of regional importance. The project leverages both robotic ELISA and Luminex multiplex high throughput platforms in order to efficiently and sustainably surveil several dozen infections/vaccinations. Sampling strategy is the pragmatic approach of age-stratified anonymized residual blood specimens from networks of 25 hospitals in Indonesia and 20 in Viet Nam. The project joins academic research partners from the University of Oxford’s clinical research units in Indonesia and Viet Nam with researchers within the respective Ministry of Health in both nations. The first year of effort focuses exclusively on serological surveillance of SARS-CoV-2 through 3 distinct workstreams: 1) establishing routine national serological surveillance by ELISA; 2) cross-sectional surveys for exposure to SARS-CoV at selected sites; and 3) following two longitudinal cohorts for serological assessment by ELISA over a 1-year period, where enrollment in one cohort immediately follows qPCR positivity for SARS-CoV-2, and in the other immediately follows vaccination against COVID-19. Year 1 will also see the optimizing and validation of a multiplex Luminex assay for six distinct SARS-CoV-2 antigenic targets and three distinct immunoglobulins (A, M, and G), along with Spike S1 and Spike N proteins of MERS-CoV, and four seasonal coronaviruses. The same multiplex assay will later include eight emerging infections (e.g. Nipah, Zika, and Japanese encephalitis viruses), neglected tropical infections (e.g., Dengue, malaria, filariasis, leprosy, and intestinal helminthiases), and vaccine-preventable infections (e.g. measles, diphtheria, and tetanus). That multiplex serological assay will constitute the basis of routine national serological surveillance, and the project aims to build that capacity within Ministry of Health facilities in Indonesia and Viet Nam, and to turn those facilities over to the respective authorities at the end of the 5- year life of the project.